India
· Delayed Price · Currency is INR Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 257.04 billion. The enterprise value is 300.39 billion.
| Market Cap | 257.04B |
| Enterprise Value | 300.39B |
Important Dates
The next estimated earnings date is Monday, July 28, 2025.
| Earnings Date | Jul 28, 2025 |
| Ex-Dividend Date | Jul 16, 2025 |
Share Statistics
Piramal Pharma has 1.33 billion shares outstanding. The number of shares has increased by 4.41% in one year.
| Current Share Class | 1.33B |
| Shares Outstanding | 1.33B |
| Shares Change (YoY) | +4.41% |
| Shares Change (QoQ) | +7.88% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 23.40% |
| Float | 611.07M |
Valuation Ratios
The trailing PE ratio is 284.37 and the forward PE ratio is 135.12. Piramal Pharma's PEG ratio is 1.48.
| PE Ratio | 284.37 |
| Forward PE | 135.12 |
| PS Ratio | 2.81 |
| PB Ratio | 3.16 |
| P/TBV Ratio | 6.36 |
| P/FCF Ratio | 112.77 |
| P/OCF Ratio | 28.81 |
| PEG Ratio | 1.48 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.79, with an EV/FCF ratio of 131.80.
| EV / Earnings | 329.63 |
| EV / Sales | 3.28 |
| EV / EBITDA | 19.79 |
| EV / EBIT | 42.83 |
| EV / FCF | 131.80 |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.60.
| Current Ratio | 1.54 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 3.36 |
| Debt / FCF | 21.31 |
| Interest Coverage | 1.49 |
Financial Efficiency
Return on equity (ROE) is 1.14% and return on invested capital (ROIC) is 3.07%.
| Return on Equity (ROE) | 1.14% |
| Return on Assets (ROA) | 2.54% |
| Return on Invested Capital (ROIC) | 3.07% |
| Return on Capital Employed (ROCE) | 5.28% |
| Revenue Per Employee | 13.62M |
| Profits Per Employee | 135,630 |
| Employee Count | 6,719 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.44 |
Taxes
In the past 12 months, Piramal Pharma has paid 3.24 billion in taxes.
| Income Tax | 3.24B |
| Effective Tax Rate | 78.02% |
Stock Price Statistics
The stock price has increased by +29.71% in the last 52 weeks. The beta is 0.08, so Piramal Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | +29.71% |
| 50-Day Moving Average | 207.17 |
| 200-Day Moving Average | 227.25 |
| Relative Strength Index (RSI) | 50.91 |
| Average Volume (20 Days) | 4,244,522 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 91.51 billion and earned 911.30 million in profits. Earnings per share was 0.68.
| Revenue | 91.51B |
| Gross Profit | 59.20B |
| Operating Income | 6.28B |
| Pretax Income | 4.15B |
| Net Income | 911.30M |
| EBITDA | 14.04B |
| EBIT | 6.28B |
| Earnings Per Share (EPS) | 0.68 |
Balance Sheet
The company has 5.21 billion in cash and 48.56 billion in debt, giving a net cash position of -43.35 billion or -32.62 per share.
| Cash & Cash Equivalents | 5.21B |
| Total Debt | 48.56B |
| Net Cash | -43.35B |
| Net Cash Per Share | -32.62 |
| Equity (Book Value) | 81.25B |
| Book Value Per Share | 61.40 |
| Working Capital | 20.31B |
Cash Flow
In the last 12 months, operating cash flow was 8.92 billion and capital expenditures -6.64 billion, giving a free cash flow of 2.28 billion.
| Operating Cash Flow | 8.92B |
| Capital Expenditures | -6.64B |
| Free Cash Flow | 2.28B |
| FCF Per Share | 1.71 |
Margins
Gross margin is 64.69%, with operating and profit margins of 6.87% and 1.00%.
| Gross Margin | 64.69% |
| Operating Margin | 6.87% |
| Pretax Margin | 4.53% |
| Profit Margin | 1.00% |
| EBITDA Margin | 15.34% |
| EBIT Margin | 6.87% |
| FCF Margin | 2.49% |
Dividends & Yields
This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 0.07%.
| Dividend Per Share | 0.14 |
| Dividend Yield | 0.07% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 15.88% |
| Buyback Yield | -4.41% |
| Shareholder Yield | -4.34% |
| Earnings Yield | 0.35% |
| FCF Yield | 0.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |